STARPHARMA WINS $26M IN FUNDING FROM US

Biotechnology firm Starpharma Holdings Ltd has won $US20.3 million ($A26.4 million) from the United States-based National Institute of Allergy and Infectious Diseases (NIAID) to develop its VivaGel vaginal microbicide for use against sexually transmitted infections. Starpharma said the funding was significant because it would accelerate VivaGel's progress to market. It also meant that VivaGel now had funding through to the start of large-scale efficacy trials.

Sydney Morning Herald (http://www.smh.com.au/news/Business/Starpharma-wins-26m-in-funding-from-US/2005/10/03/1128191638251.html)